However, surprisingly, based on a high expression of IL-23 and IL-23R in CD133+ ovarian CSLCs derived from cancer cell lines and primary cancer tissue, we found autocrine IL-23 could promote the self-renewal capacity and tumorigenic potential of CD133+ ovarian CSLCs both in vitro and in vivo. This evidence concerns the gene IL37 and cancer.